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1 
INTRODUCTION 
 
Nutritional deficiency may also be the cause of a genuine optic 
neuropathy, which is sometimes associated with involvement of the 
peripheral nervous system.1With the exception of vitamin B12, no 
specific nutrient deficiency has been conclusively proved to cause optic 
neuropathy in humans.2  
 The pathophysiological mechanisms which are involved in toxic 
and nutritional optic neuropathies affect biochemical pathways involved 
in cell energetic production, correction of oxidative stress and quenching 
of free radicals causing papillomacular bundle damage.1,3In the current 
scenario , the treatment is limited to the intensive use of vitamins with 
variable results in individual cases, and also to the implementation of 
preventive measures, when feasible.1,4,5 
 As this entity is mostly a disease of exclusion, with a blanket cover 
diagnosis; and with prompt probing into the etiology with directional 
history, clinical examination and specific investigations , the underlying 
cause can be identified and addressed for maximal patient benefits and 
improving morbidity in the long run. 
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REVIEW OF LITERATURE 
The optic nerve is susceptible to damage from various toxins, 
including drugs, methanol, metals, organic solvents and probably some 
sort of tobacco.6This group of disorders is named as toxic optic 
neuropathy (TON) and is characterized by bilateral visual loss, reduction 
of colour vision and central or cecocentralscotoma. Toxic optic 
neuropathy may be triggered or just aggravated by nutritional deficits, 
including the vitamins cobalamin (B12), folic acid, thiamine (B1), 
riboflavin (B2), niacin (B3), pyridoxine (B6) and proteins with  amino 
acids.  
For example, among malnourished and intoxicated patients, both 
factors usually play an equal  role contributing to the TON. Because of 
people’s greater exposure to toxic substances in environment and food, 
and coexisting malnutrition.they are more prevalent in developing 
countries,. No age, gender and racial predilections have been 
demonstrated. The existence of a nutritional deficiency often constitutes 
the predisposing factor that produces symptoms of optic nerve 
involvement in the presence of toxins, including iatrogenic ones, or in a 
genetically predisposed population7-10. 
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The disruption of biochemical mechanisms involved in the 
correction of oxidative stress appear to be a common mechanism in these 
different forms of optic neuropathies11. It should be noted that the earliest 
possible diagnosis allows better treatment of the nutritional deficit or the 
toxic disorder and helps in the prevention of late sequelae. In fact, with 
the earliest diagnosis, the optic nerve injury tends to be more reversible. 
Tobacco alcohol amblyopia is an outdated term that was used to 
describe visual impairment as a result of tobacco and alcohol abuse 
accompanied usually by nutritional deficiencies12,13. The visual 
impairment usually presents as a centrocecalscotoma with 
dyschromatopsia. Its incidence is declining likely with time, secondary to 
nutritional supplementation which seems to indicate a major role of 
vitamin deficiency. Hence the disease process was renamed as Nutritional 
Optic Neuropathy. 
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MECHANISM OF OPTIC NEUROPATHIES 
The mechanism  of nutritional or toxic optic neuropathies is  
certainly  not unique. Several substances have been suggested  including 
riboflavin, glutathione, cyanides or zinc . The mechanisms involvedare 
complex and includes a number of effective hydrosolubleor liposoluble 
quenchers of oxygen and free radical orthe cofactors of these reactions. 
Theconcentration or availability of some of the anti-oxidantsplay a 
majorprotective role against the development of optic neuropathies 
despite exposure to toxins.This corrective system of oxidative stress play 
a role, in the worsening of opticneuropathies secondary to glaucoma, 
directly or indirectly. On theone hand, oxidative stress interferes 
remodelling the collagen and elastin of the extracellular matrix and 
affects the structure of thetrabeculum . On the other hand, the existence of 
an oxidative stress expresses the production of large quantities offree 
radicals. It can be postulated that free radicals interferein the modulation 
of apoptosis of ganglion neurons. The combination of anti-oxidant and 
nutritional factors appearsto have future therapeutic implications. 
However, the pathophysiology responsible for this condition is still 
poorly understood and multiple mechanisms have been suggested. 
Tobacco, alcohol and vitamin deficiencies all contribute either in 
combination or individually. Patients with Leber's Hereditary Optic 
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Neuropathy (LHON) gene mutation are more prone to acquire tobacco 
alcohol amblyopia. The common underlying mechanism postulated is the 
impairment of mitochondrial oxidative phosphorylation which explains 
the overlap between the two conditions14-16. Nicotine and cyanide from 
tobacco play a role in causing the optic neuropathy17. In addition both the 
alcohol and tobacco lead to production of free radicals exerting a direct 
toxic effect. This may also explains the therapeutic effects of vitamins 
such as riboflavin which acts as an antioxidant., Malnutrition, thiamine 
deficiency, gradual accumulation of formic acid, poor B12 absorption 
secondary to alcohol and toxic byproducts like cyanide act together to 
cause neuropathy. It is considered to be different from other toxic 
amblyopia due to its insidious onset and reversibility of symptoms. 
 The optic nerve is susceptible to various pathologic processes such 
astraumatic vascular, inflammatory, toxic, nutritional, compressive, 
infiltrative, hereditary, and. The clinical findings such as visual field, 
visual acuity, color vision help to distinguish among the various causes 
and guide in the workup. A metabolic optic neuropathy is defined as 
dysfunction of optic nerve caused by an exogenous substance that causes 
relatively selective damage to the optic nerve (toxic optic neuropathy) or 
a nutritional deficiency that impairs optic nerve function (nutritional 
deficiency optic neuropathy). A hereditary optic neuropathy defines optic 
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nerve damage that is secondary to an underlying genetic disease that 
includes optic neuropathy as a major component of its phenotype.These 
conditions are classifiedunder a broader category of mitochondrial optic 
neuropathies. 
Impaired papillomacular bundle causes specific clinical findings, 
including (1) decreased visual acuity, (2) impaired color perception, (3) 
central (involving fixation only) or cecocentral (involving  fixation and 
the blind spot) visual field defects and (4) temporal disc pallor. 
        Toxic optic neuropathy is a complex multi-factorial disease affecting 
individuals of all ages and races worldwide. Etiologically it includes 
nutritional factors like B-complex vitamins deficiency and toxic factors, 
especially  alcohol abuse and tobacco use. The condition also leads to 
morbid metabolic, neurologic effects and even death.  
Methanol which is an organic solvent,is cheap and easily available. 
It is used frequently in adulterated alcoholic beverages18. The major 
factor that is responsible for the adverse effects is not methanol itself but 
its metabolite formic acid, which due to slow clearance produces toxic 
effect. Patients with alcohol related toxic optic neuropathy present with a 
bilateral progressive painless loss of visual acuity, dyschromatopsia, 
subsequent optic disc changes including temporal disc pallor and retinal 
nerve fiber layer loss mainly in papillomacular bundle19. Although there 
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is no specific treatment; early detection and prompt management may 
decrease visual impairment. 
CLINICAL APPROACH TO A CASE OF OPTIC NEUROPATHY  
TIME COURSE OF VISUALLOSS 
Time course is an useful feature for determining pathogenesis. 
Abrupt onset upon awakening is characteristic of ischemic optic 
neuropathy. Acute onset over a few days suggests optic neuritis. 
Compressive lesions causesslowly progressive visual loss over months to 
years. Subacute visual loss ranging from weeks to months is 
characteristic of toxic/nutritional optic neuropathies. Subacute loss that is 
bilateral and sequential (i.e.,one eye then the other) is the typical mode of 
onset of Leber’s Hereditary Optic Neuropathy. Congenital anomalies of 
the optic disc, remote trauma, and amblyopia present static visual loss. 
Optic nerve dysfunction due to papilledema is often preceded by episodes 
of transient visual obscuration, typically precipitated by postural change. 
PAIN 
The presence of eye pain, especially pain on eye movement, is 
highly suggestive of optic neuritis and helps to distinguish this condition 
from Non Arteritic Anterior Ischemic Optic 
Neuropathy,Leber’sHereditary Optic Neuropathy,  Toxic and Nutritional 
Optic Neuropathy which are usually painless. 
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Patients with raised intracranial pressure due to 
pseudotumorcerebri usually have headache but some may complain of 
mild eye ache and pressure sensation. 
Patients with AION dueto Giant Cell Arteritis  usuallycomplain of 
scalp tenderness, rather than headache.  
VISUAL FIELD DEFECTS 
Altitudinal defects are characteristic of AION and of glaucoma. A central 
scotoma is the most common field defect in optic neuritis. Bilateral 
central or centrocecalscotomas is characteristic of toxic-nutritional optic 
neuropathies and of LHON. Intracranial optic nerve and/or chiasmal 
compression should be suspected in patients with temporal hemianopic 
defects, either unilateral or bilateral,. Chronic papilledema causes 
physiological blindspotenlargement and inferior nasal constriction early, 
and generalized constriction in the late stages. 
DISC APPEARANCE 
          Optic disc changes are nonspecific, but associated features can be 
helpful. Segmental edema is characteristic of AION. The combination of 
edema and pallor, when acute, should be considered for arteritic AION. 
When disc edema is bilateral, increased intracranial pressure should be 
considered  if vision is normal and arteritic AION if vision is markedly 
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reduced. Pallor may be diffuse or focal. Segmental pallor suggests prior 
disc ischemia. Band atrophy (temporal and nasal pallor) is usually 
associated with temporal hemianopic loss (usually compressive). Pallor 
with optociliary shunt vessels is mostly seen in long-standing optic nerve 
sheath meningiomas and with chronic disc edema of any cause. 
IMAGING 
Although in most optic neuropathies the diagnosis is made from 
the clinical features, a few ancillary tests can be useful. Computerized 
tomographic (CT) scanning is usually effective in demonstrating 
intraorbital optic nerve compression, but is less sensitive for intracranial 
mass lesions visualization. CT is particularly well-suited for detecting the 
calcification sometimes seen with optic nerve sheath meningiomas and 
optic disc drusen. Magnetic resonance imaging (MRI) provides better 
spatial resolution in visualizing intracranial optic nerve compression, but 
is inferior to CT scanning for orbital imaging. Hence an adequate MRI 
should include axial and coronal views with fat suppression and 
gadolinium. Visual Evoked Potential (VEP) testing may yield useful 
information to a certain extent. The VEP is particularly sensitive for 
demyelination but relatively insensitive for most other types of optic 
neuropathy. 
MITOCHONDRIAL OPTIC NEUROPATHIES 
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The conditions included under this category are 
 Heriditary optic neuropathy 
 Toxic – Nutritional optic neuropathy 
HEREDITARY OPTIC NEUROPATHIES 
       Inherited optic neuropathies commonly affect the papillomacular 
nerve fiber bundle, causing central vision loss, decreased visual acuity, 
dyschromatopsia, and central or cecocentralscotomas. The time course is 
the most useful feature in distinguishing specific forms. The most 
common hereditary optic neuropathies are Dominant Optic Atrophy and 
Leber’s Hereditary Optic Neuropathy. 
 
Dominant Optic Atrophy 
Dominant optic atrophy (DOA), or Kjers optic neuropathy, 
typically begins during the school-age years and produces slowly 
progressive loss of central vision over a lifetime. There is enormous 
variability in presentation, both inter- and intrafamilial, including 
occasional individuals with 20/20 visual acuity and only mild 
dyschromatopsia20. 
Consequently, patients with this disorder may be not aware of other 
affected family members. The characteristic optic disc excavation seen in 
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this condition can be mistaken for glaucoma causing further diagnostic 
confusion. Bygenetic linkage studies the responsible gene ws mapped to 
an area on the long arm of chromosome 3, termed the OPA 1 locus.The 
biochemical consequences of this mutation are unknown yet and there is 
stil no known treatment.21-24 
Leber’s Hereditary Optic Neuropathy 
Leber’s hereditary optic neuropathy (LHON) is one among a 
multitude of conditions that bear his name. Mostly it presents as subacute 
painless loss of central vision followed by similar loss in the fellow eye 
weeks to months later. It usually affects young men. Recent advances in 
molecular genetics have played a major role in our understanding of 
LHON and have led to the development of a reliable blood test for this 
disorder. Previously, this entity was defined purely on clinical grounds, 
hence cases that differed from our idea of what “classic” LHON should 
present like were not included. 
LHON is due to a point mutation within the mitochondrial genome that 
eventually leads to breakdown of cellular energy production. Certain 
mutations are associated with a better visual prognosis. The trait is 
transmitted exclusively by women which is consistent with mitochondrial 
inheritance,. All offspring of female carriers would receive the mutation 
but some will remain unaffected. 
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Men express the trait more likely than women, for which reasons 
remain unclear. Examination typically shows bilateral central scotomas 
and varied optic disc appearance. Absence of leakage on fluorescein 
angiography distinguishes true disc edema from characteristic thickening 
of the nerve fiber layer (termed pseudoedema) and capillary hyperemia 
(termed circumpapillarymicroangiopathy). 
This ophthalmoscopic appearance is sometimes even present for 
years prior to the onset of visual loss and is also seen in some unaffected 
carriers of the LHON mutation. In some cases, the optic nerve head 
appears normal even during the acute phase of visual loss, with eventual 
onset of pallor. Late phase LHON may present as optic atrophy which 
may be difficult to distinguish from other causes of optic neuropathy. 
 In most affected individuals, visual loss is considered to be the 
only clinical manifestation of the LHON mutation. Some of the patients 
demonstrate cardiac conduction defects and some may show minor 
neurological abnormalities. In addition, there are well-described group of 
patients, mostly women, with LHON who develop clinical and laboratory 
signs of multiple sclerosis. The basis for this association is unclear. 
Multiple sclerosis patients in whom the severity of visual loss is out of 
proportion to other clinical manifestations should be tested for the LHON 
mutations. 
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 Magnetic Resonance Imaging is especially suggested to rule out 
demyelinating disease and compressive lesions 
 The basis behind male predominance (80–90% of cases) is  
stillunclear. The long and varying latency period before the onset of 
visual loss, the rapid decline of vision once it begins to fail, and the 
subsequent long-term stability of vision after the acute phase is still not 
understood. Environmental factors such as smoking, diet, and toxic 
exposure may play an aggravating role in the expression of the LHON 
mutation. Affected individuals and carriers should be strongly advised 
regarding these lifestyle issues. 
TOXIC-NUTRITIONAL OPTIC NEUROPATHIES 
      Toxic and nutritional optic neuropathies are frequently grouped 
together since they share common clinical features and because of the 
difficulty involved in distinguishing between their relative contributions 
in many cases. For example, the visual loss of “tobacco-alcohol 
amblyopia” can be reversed by supplying appropriate vitamin 
supplements in the absence of smoking and alcohol consumption. 
       Optic neuropathies due to toxins and to nutritional deficiencies 
usually present with subacute onset of bilateral central visual loss which 
manifest as decreased visual acuity, cecocentralscotomas, and 
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dyschromatopsia. The optic discs may appear hyperemic in the initial 
stage; temporal pallor is a late finding. Similar clinical features also occur 
in Leber’s hereditary optic neuropathy and it has been suggested that each 
of these optic neuropathies may share a common pathophysiological 
basis. The basis behind the selective vulnerability of the papillomacular 
bundle in these syndromes is not entirely understood. It may be 
associated with the high concentration of parvocellular ganglion cells in 
this region. These cells exhibit a higher maintained firing rate and a 
greater surface to volume ratio when compared tomagnocellular ganglion 
cells and hence may be more susceptible to deficits in energy metabolism. 
More specifically, a deficiency of available adenosine triphosphate may 
contribute to the visual loss in these forms of optic neuropathy. 
 The concept of a failure of energy production within retinal 
ganglion cells, being the cause of visual loss would be consistent with the 
capacity for delayed recovery in some cases rather than a primary 
demyelination of the optic nerve,.Mitochondrial injury and imbalance of 
intracellular and extracellular-free radical homoeostasis is generally 
accepted to be the common pathway for toxic and nutritional optic 
neuropathies, for at least some of the toxins,. 
History 
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 Drug or toxin exposure: in a workplace (e.g. heavy metals, fumes, 
solvents, etc), ingestion of materials or food and use of a systemic 
medication; 

 Social history and habits (e.g. amount and sort of tobacco and 
alcohol used), diet (e.g. any specific diets used), anorexia nervosa, 
gastrointestinal disease or surgery or anaemia.25 
 Some metabolic diseases, including diabetes mellitus, kidney 
failure and thyroid disease, might play a role in influencing TON 
due to the accumulation of toxins. 
 A family history should also be taken into consideration to identify 
hints on hereditary optic nerve disorders. On the other hand, if 
alcohol or drug addiction is suspected, information from family 
members or friends might contribute.  
   History of presenting illness should be probed towards symptoms that 
include sensory disturbances in the extremities and gait problems, 
indicating toxic peripheral neuropathy and/or toxic effect upon the 
cerebellum. Patients’ complaints include the following: loss of visual 
acuity (acute or chronic), decreased contrast perception, a blur in the 
centre when reading (continuously and slowly progressing), faded colours 
(particularly red) or a general loss of colour perception. All of these 
symptoms are never accompanied by any ocular pain.  
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Clinical presentation 
       This diagnosis should be suspected in cases with decrease of the 
visual acuity of variable intensity ranging from simple blurriness to 
severe visual loss. Cases with blindness are rare or very late and those are 
irreversible. Course of involvement is slowly progressive over several 
months, definitely painless and classically bilateral. Nevertheless, it is not 
rare to observe a unilateral, or at least asymmetric deficit, particularly 
when the nutritional deficit and the intoxication are recent. Anisocoria is 
usually absent; Mostlythere is no relative afferent defect in these cases 
because the optic neuropathy is always bilateral and symmetric. 
However, in most patients, pupils are bilaterally sluggish in reacting to 
light. The pupillary light reflex, both direct and consensual, is discreetly 
impaired with presence of an afferent pupillary defect (Marcus Gunn 
phenomenon) is more evident when the optic nerve involvement is  
asymmetric. 
Nevertheless, there are many atypical forms. Hence, the ingestion 
of small quantities of methanol (methyl alcohol), most often in the form 
of illicit alcoholic drinks, is in fact responsible for an optic neuropathy 
both “nutritional and toxic,” that evolves more rapidly. The decrease in 
visual acuity may often be preceded or accompanied by phosphenes. 
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Visual loss is most severe and is also sometimes irreversible 
resulting in optic nerve atrophy. In addition to the signs and symptoms 
suggestive of this intoxication (nausea, vomiting, and disturbances of 
consciousness leading to coma, severe acidosis with a large anion gap 
requiring intensive care treatment), the early loss of the light reflex is an 
additional hint in favor of this etiology.  
The concept of the optic nerve head change is not contributory in 
the context of toxic and nutritional optic neuropathies. It is mostusually 
normal indicating the existence of a retrobulbar optic neuritis. 
Nevertheless, optic nerve head changes consistent with an anterior 
ischemic optic neuropathy with peripapillary hemorrhages or even 
papilledema could be suggestive of nutritional optic neuropathies 
associated with toxins. The presence of obvious optic atrophy remains 
rare in the context of these “nutritional” neuropathies, isolated or not. 
This presentation as optic atrophy is suggestive of a late stage which is 
irreversible. The functional prognosis becomes reserved despite of 
returning to a normal food balance and the stop of an eventual 
intoxication. 
It depends not only on the intensity of the alimentary insufficiency 
but also on personal and social factors.  Thus, a nutritional optic 
neuropathy associated to a toxic factor can be detected by a careful follow 
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up of patients receiving high-risk treatments or subjects exposed to 
dangerous environments. 
Early decrease in mesopic visual acuity may be found and scotopic 
vision (rod mediated monochromatic vision) is usually low, while the 
photopic visual acuity (i.e., under well-lit conditions) is preserved.  
But, these tests are not performed routinely. Color vision or 
chromatic sense is abnormal even in the earliest stages of the disease. The 
color vision defect usually involves first the “blue– yellow” axis 
preceding a characteristic “red–green” axis. In a similar way , visual 
fields are always abnormal. The type of abnormalities found varies 
according to the pathophysiological mechanism leading to optic nerve 
neuropathy and this is clearly correlated to the causal etiology. Examples 
include the enlargement of the blind spots of Mariotte which may result 
from papilledema; a cuneiform scotoma leaving the papilla is due to 
peripheral fasciculus involvement; bilateral and symmetrical 
cecocentralscotomas, sometimes associated with a concentric narrowing 
of the visual field, may result from papillomacular bundle involvement 
and this constitutes the most characteristic aspect of the nutritional optic 
neuropathies, either pure or in association with toxins26. The study of 
visual evoked potentials (VEP)confirms the presence of subclinical 
abnormalities in earlier stages. VEP is also useful when it is mandatory to 
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confirm the involvement of the optic pathways. The ophthalmologic 
examination does not rule out the other etiology definitely to explain the 
functional deficit. But still the VEP abnormalities such as lengthening of 
peak times and reduction of amplitudes are non-specific and do not orient 
towards a specific etiology. Similar changes can occur in a wide range of 
clinical settings such as toxic, hereditary or inflammatory conditions27. 
Varioustests must be performed in order to confirm nutritional 
etiology of the neuropathy. It is also done to eliminate certain specific 
causes that would need to be addressed. Neuroimaging must be obtained 
when optic nerve involvement is suspected and eventually repeated 
looking for a compressive lesion of the optic pathways with such an 
atypical clinical presentation that it could resemble a nutritional 
deficiency or a toxic component as etiology with progressive and 
insidious evolution. Cerebrospinal fluid (CSF) studies are not routinely 
performed but must be done to rule out certain inflammatory, tumoral or 
toxic etiologies. In fact these lesions are very frequent in the context of 
the nutritional deficits. Finally, other ocular (i.e., keratitis) or systemic 
manifestations (i.e., skin lesions) must be searched for because they are 
frequently observed with dietary or vitamin deficiencies. 
 
Clinical Examination 
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The course of loss of visual acuity is usually progressive, painless 
and bilateral. It begins with the blur at the point of fixation (a relative 
scotoma) and is followed by a progressive decline. It ranges from 
minimal reduction to no light perception (NLP) in rare cases (e.g. 
methanol ingestion). Most patients reach 20 of 200 or better. Relative 
afferent pupillary defect (RAPD) is usually not present because the optic 
neuropathy is always bilateral and symmetric. The pupils often react only 
to strong light bilaterally with an adequate constriction, but they usually 
respond normally to near stimulation.  
Clinically, in most cases pupillary reaction does not differ visibly 
from a normal population. Dyschromatopsia is a typical feature which 
can be tested with colour vision tests such as Ishihara plates or, still better 
because also blue deficits are included and Panel D 15 test. However, it 
has to be kept in mind that at least 7% of men and 0.3% of women have a 
colour vision defect which is congenital. In these cases, the anomaloscope 
frequently shows typical results, different from those seen in acquired 
colour vision deficits that cannot be designed to a classical congenital 
colour vision disorder. 
Fig 1: Ishihara chart 
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 In the early stages, most of the patients have normal-appearing 
optic discs, but disc oedema and hyperaemia may occur in some acute 
poisonings. Disc haemorrhages may also be present. Thereafter, 
papillomacular bundle loss and optic atrophy develop,which initially 
present as temporal pallor of the optic disc. 
 Visual field (VF) test is of major importance in any patient 
suspected of having TON. It reveals symmetrically central or 
cecocentralscotoma, initially as relative scotoma, with preservation of the 
peripheral field. Defects are characterized by soft margins, which are 
easier to plot for coloured targets, such as red, compared to a white 
stimuli. 
 
INVESTIGATIONS 
BLOOD INVESTIGATIONS 
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Laboratory studies include complete blood count, blood biochemistries, 
urinalysis and a serum lead level; identification of a specific toxin (such 
as methanol) or its metabolites in the patient’s blood or fluids; screening 
of the blood and urine for other toxins if exposure to a particular one is 
not identified based on history (e.g. heavy metal screening). Serum B-12 
(pernicious anaemia) and red cell folate levels (marker of general 
nutritional status) need to be obtained to exclude NON. Other tests that 
reveal nutritional imbalance include direct or indirect vitamin assays, 
serum protein concentrations and antioxidant levels. Serologic testing for 
syphilis is also recommended. Altered liver enzymes may indicate 
alcoholism. It is better advisable to contact a legal medical and/or 
industrial medical centrewho is experienced with toxicological tests. 
NEUROIMAGING 
 Imaging studies include MRI of the optic nerves, chiasm with and 
without gadolinium enhancementand  is usually performed to exclude a 
compressive lesion, and it is normal intypical case of  TON. In methanol 
intoxication, it may reveal degeneration of the basal ganglia. 
ELECTROPHYSIOLOGICAL TESTS 
     Visual-evoked potentials (VEP) and the pattern electroretinography 
(PERG), may also be useful. VEP may be useful in patients with early or 
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subclinical optic neuropathy. Itis  used to differentiate from 
demyelinating disease. VEP usually reveals normal or near normal 
latency with significantly reduced amplitude of P100. In most cases, 
demyelinating disease would become visible in MRI as well. The P50 and 
N95 components of PERG reflect macular and retinal ganglion cell 
function, respectively. PERG is useful in a patient with abnormal VEP to 
identify a macular lesion. ERG or still better multifocal ERG may be used 
to exclude a retinal disease. ERG, contrast sensitivity (CS) measurements 
and retinal nerve fibre layer thickness by OCT are also recommended to 
detect subclinical toxicity of drugs, such as antibiotic, antimetabolite or 
antituberculosis medicines in an early stage.  
 DIAGNOSIS 
Diagnosis is based on the identification of a toxic factor and 
exclusion of any other pathologies giving a very similar clinical picture. 
Differential diagnosis include LHON, dominantly inherited optic 
neuropathy, compressive or infiltrative lesion of optic chiasm, bilateral 
inflammatory ordemyelinative optic neuropathy, maculopathies, macular 
dystrophies, retinal degenerations such as cone dystrophy, syphilitic optic 
neuritis, Graves disease, radiation optic neuropathy, diabetic papillopathy 
and non-organic visual loss (hysteria/malingering).  
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Toxic optic neuropathy is usually a diagnosis of exclusion. Hence, 
the procedures necessary for the diagnostic approach could not be easily 
specified.  
 Treatment includes removing the toxic substance (e.g. 
discontinuation of the drug), cessation of smoking and alcohol 
consumption. Follow up examinations should be continued initially every 
4–6 weeks and include visual acuity, colour vision, visual field, pupil 
reaction and optic disc examination. 
Prognosis usually depends on the dosage and duration of exposure 
to toxic substance. In most cases, after discontinuation, vision improves 
to normal over several days or weeks. It is known that TON is dose and 
duration dependent and occurs more often with antituberculosis drugs 
such as ethambutol and isoniazid, some antimicrobial agents such as 
linezolid, ciprofloxacin, cimetidine and chloramphenicol, antiepileptic 
drugs (vigabatrin), disulfiram (for chronic alcoholism), halogenated 
hydroquinolones (amebicidal medications), antimetabolites (e.g. 
methotrexate, cisplatin, carboplatin, vincristine and cyclosporin), 
tamoxifen and sildenafil. In these cases, especially when drugs are used 
for longer periods or with higher dosage, patients should be informed 
about possible toxicity in prior and educated to report for any visual 
problems immediately  
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Ethambutol 
Ethambutol is used in treatment against tuberculosis and 
Mycobacterium avium infections. Optic neuropathy belongs to most 
serious adverse effects related to ethambutol use. It occurs in up to 6% of 
patients who taking the drug. In general the clinical picture is similar to 
other toxic optic neuropathies, including early occurrence of 
dyschromatopsia.  
Common field defect encountered is central or centrocecalscotoma. 
Less common field defects include peripheral constriction, altitudinal 
field defects, and bitemporal field defects .29,30 
.Visual problems do usually not occur during the first 2 months of 
ethambutol treatment, and they generally appear between 4 and 12 
months. Renal dysfunction might shorten this period by decreasing the 
excretion of the drug and increasing its serum levels. It was proposed that 
the risk of optic neuropathy was higher at that dosages of 25 mg/kg/day 
or more. In such a case, the dosage should be reduced to 15 
mg/kg/day.This is considered both relatively safe and effective. However, 
even with much lower doses, cases of vision loss have been reported. The 
exact pathophysiology mechanism of ethambutol induced optic 
neuropathy is unknown.  
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The ocular toxicity is dose and duration dependent; hence, early 
recognition of TON and prompt cessation of the therapy is important in 
preventing further progression of vision loss. Standard methods used for 
monitoring ethambutol use include visual acuity assessment, visual field 
testing, funduscopy, colour vision testing, contrast sensitivity 
measurement, OCT and VEP. It was shown that the use of 3D computer-
automated threshold Amsler grid testing (3DCTAG) with 0.5° grid 
spacing revealed relative scotomas that had been missed by both standard 
visual field testing methods and 3DCTAG with 1° grid spacing . Visual 
acuity and colour vision testing are some of the easiest tests that can also 
be performed by non-ophthalmologists, especially important in countries 
where only few specialists are available. 
International guidelines on prevention and early detection of 
ethambutol –induced ocular toxicity have been published. But still, 
opinion of the clinical effectivenessof regular vision tests to enable early 
detection of toxicity is divided.Other than cessation of the the drug, no 
specific treatment is available for optic neuropathy caused by ethambutol. 
Once this is accomplished, many patients will recover, and this may take 
weeks to months.However, there arecase reports that vision may still 
decline or fail to recover even the drug is stopped if damage is severe 
enough. 
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Isoniazid 
This is another antitubercular drug able to induce optic neuropathy. 
This TON may be associated with bilateral optic disc swelling with 
concurrent bitemporalhemianopicscotomas. Vision improves when 
administration of the drug is ceased.Pyridoxine 25-100mg/day may help 
stabilize or even reverse isoniazid induced toxic optic neuropathy. 
Though it has been used to reverse the toxicity of isoniazid, the 
improvement may simply be due to stopping the drug and not the 
pyridoxine. 
 Because both ethambutol and isoniazid may be given concurrently 
in the treatment of tuberculosis, and both may produce a TON, clinicians 
should remember that if stopping one does not result in improvement of a 
patient’s vision, then the other drug should be stopped. 
Methanol 
Methanol is metabolized to formic acid and this is responsible for 
its toxicity . This originates from a combined effect of metabolic acidosis 
and an intrinsic toxicity of the formiate anion itself. Severe poisoning 
causes nausea, vomiting and abdominal pain and affects the central 
nervous system in a similar way as ethanol. 
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It is believed that visual symptoms are due to mitochondrial 
damage and suppression of oxidative metabolism by inhibiting 
cytochrome oxidase activity resulting in hyperaemia,oedema and optic 
nerve atrophy. It was also shown that methanol causes retina damage, 
including change in the molecular structure and orientation of rhodopsin 
in cell membranes of the retina and an impairment of ERG. 
Ocular symptoms occur in half of the patients. They may develop 
after 6 hours or more after ingestion and include: blurred vision; 
photophobia; visual hallucinations, such as ‘a snowstorm, partial to total 
visual loss and, rarely, eye pain. Ocular examination usually reveals 
normal to constricted visual field, sluggish or non-reactive pupils, 
nystagmus, hyperaemic optic discs, papilloedema, retinal oedema and 
haemorrhages and reduced to absent vision. 
The most common acute field defect is a central scotoma. 
Methanol poisoning is a life-threatening disease; therefore, its ocular 
complications are usually of secondary importance. However, the visual 
symptoms help to make the diagnosis, thus leading to an early start of the 
appropriate therapy. Prognosis is  correlated with the severity of the 
acidosis  rather than with serum methanol concentrations. 
Besides the antidote therapy – using fomepizole or ethanol to delay the 
metabolism of methanol – intravenous steroid use was recently proposed.  
29 
Linezolid 
Linezolid belongs to the group of oxazolidinone antibiotics. It 
shows activity against methicillin-resistant Staphylococcus species, 
penicillin resistant Streptococcus species and vancomycin-resistant 
enterococci. Recommended therapy duration extends upto 28 days. 
Usually, it is well tolerated with only a few adverse effects. In most cases 
after discontinuation of the therapy, optic neuropathy improved, but a 
residual deficit in central visual acuity remained. The outcome is 
comparatively favourable. Mitochondrial dysfunction is suspected to be 
the cause of neurotoxicity. Specifically, low folate levels cause the 
plasma homocysteine level to increase, which may inhibit neuronal 
mitochondrial function. 
Antitumor Necrosis Factor Alpha (TNF-a) Agents 
Antitumor necrosis factor alpha (TNFa) agents have been used in 
treatment of a wide range of inflammatory diseases, including rheumatoid 
arthritis, inflammatory bowel disease, psoriatic arthritis and refractory 
uveitis. The drugs licensed for clinical use are as follows: etanercept, a 
dimeric fusion protein blocking the effect of TNF-a; infliximab, a 
chimeric monoclonal receptor antibody; and adalimumab, a human 
monoclonal TNF-a antibody. 
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Other Drugs 
Vigabatrin 
          This is an antiepileptic medicine which is used for infantile spasms 
and refractorycomplex partial seizures. Visual field defects occur in 15–
31% infants, 15% children and 25–30% adults. They usually begin as 
bilateral nasal defects and progress to concentric bilateral field 
constriction with preservation of central vision. Vigabatrin-associated 
visual field defects may be irreversible. The time of onset of visual field 
defects is age and duration dependent: 3 months in  infants, 11 months in 
children and 9 months in adults. These visual field changes are probably 
related to both retinal and optic nerve toxicities. It is recommended to 
monitor visual fields before starting the treatment with vigabatrin and at 
regular 6-month intervals thereafter (infants in 3-month intervals). 
Taurine deficiency is a cause of vigabatrin- induced retinal phototoxicity. 
Ciprofloxacin 
 Ciprofloxacin is an antibiotic used to treat a wide range of 
infections. Ocular adverse effects are rare. Blurred vision, changes in 
colour perception, decreased visual acuity and ocular pain are noted to 
occur in <1% of cases . 
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 The mechanism of ciprofloxacin induced optic neuropathy remains 
unknown. It is important to be aware of adverse effects including the 
possibility of toxic optic neuropathy, particularly in those patients who 
are on high dose or prolonged treatment courses. After discontinuation of 
ciprofloxacin therapy, a 6-month testing of visual acuity, visual field and 
colour vision is recommended. 
Dapsone 
There are also two cases reported in the literature ondapsone-
induced optic neuropathy.  
Amiodarone 
Amiodarone is an iodinated benzofurane derivative used initially for the 
treatment of refractory ventricular arrhythmias and more recently for 
supraventricular rhythm disturbances as well. Its amphiphilic nature 
causes the drug to accumulate in lysozymes, thus altering their function. 
Neurological side effects include peripheral neuropathy, ataxia and 
tremor, and generally indicate toxicity. The most common ocular 
manifestation is a form of feathery crystalline deposit in the cornea 
termed cornea verticellata and is termed vortex keratopathy.Such corneal 
changes occur at therapeutic levels and are usually asymptomatic. Less 
commonly, patients develop a form of optic neuropathy characterized by 
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disc edema that may be segmental or generalized with normal or only 
mildly reduced optic nerve function.Most cases are bilateral and most 
resolve when the drug is reduced or discontinued. In some cases, 
significant visual loss occurs, perhaps due to underlying anatomic 
predisposition (crowded discs) and/or atherosclerotic changes in disc 
vasculature. The presumed mechanism for amiodarone optic neuropathy 
involves diffusion of the drug into choroidal interstitial fluid via 
fenestrated capillaries in the peripapillary region (i.e., through a gap in 
the blood–retinal barrier). 
 A similar clinical presentation (bilateral disc edema with normal 
optic nerve function and normal intracranial pressure) has been attributed 
to cyclosporine neurotoxicity. 
Digoxin  
Cardiac glycosides affect many different tissues including eye and 
brain. Visual symptoms occur in 95% of patients with digitalis toxicity 
and are thought to be due to inhibition of sodium-potassium-activated 
ATP-ase in retinal cones and/or ganglion cells. Xanthopsia (yellow 
vision) is the most common manifestation of digitalis toxicity. 
Patients with symptomatic digitalis toxicity often complain “frosty” or 
“hazy” vision. Positive visual phenomena are common which includes 
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sparkles, flashes, flickering, and shimmering.Some patients complain of 
glare or dazzle. These visual phenomena may be mistakenly attributed to 
a variety of other causes, such as cataracts, vitreous traction, migraine, or 
vertebrobasilar insufficiency. Visual symptoms may occur in the absence 
of any other manifestations of digitalis toxicity and may occasionally 
occur even with therapeutic levels.  Digitalis toxicity can occur without a 
recent change in dosage. 
Tobacco-Alcohol Amblyopia– Misnomer 
 The term ‘tobacco-alcohol amblyopia’ is often misleading. It is not 
an amblyopia but an optic neuropathy and it has never been proven that it 
is really caused by an interaction or synergism of alcohol and tobacco. 
However, there are patients who are heavily smoking and alcohol 
addicted that develop a characteristic optic neuropathy with bilateral 
visual loss. 
           In developed countries, this type of toxic-nutritional optic 
neuropathy most commonly occurs in the setting of alcohol abuse. Most, 
though not all, thiscondition occur in patients who also smoke; rare cases 
of optic neuropathy occur in patients with excessively high tobacco 
consumption (usually cigar or pipe smokers) unassociated with 
alcoholism or nutritional deficiency. Patients with tobacco-alcohol optic 
neuropathy suffer from a variety of nutritional deficiencies, generally on 
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the basis of decreased intake (obtaining most of their caloric requirements 
from alcohol). Tobacco use may contribute by increasing levels of 
cyanide and also of free radicals although there is yet no firm 
experimental data to support this theory. 
        Patients suspected of tobacco-alcohol amblyopia should also be 
evaluated for B-12 deficiency, which is an important, treatable cause of 
optic neuropathy. Of note, serum B-12 levels in the low-normal range can 
occasionally cause neurological dysfunction, including visual loss. In 
these circumstances, bone marrow and urinary methylmalonic acid levels 
should be checked as well. In addition, rare cases of transport protein 
deficiency can also produce B-12 “deficiency” in the face of completely 
normal B-12 levels. Neurological manifestations of B-12 deficiency may 
occur in the absence of any hematologic changes. 
 In making a diagnosis of alcohol-tobacco optic neuropathy, it is 
difficult to establish that the patient is in fact malnourished. The diagnosis 
is untenable in an individual who appears well-nourished and/or reports 
regular use of vitamin supplements, regardless of the amount of alcohol 
consumed. Any patient whose visual loss seems out of proportion to their 
nutritional status should be worked up for the mitochondrial mutation of 
LHON. Moreover, the nutritional status, which may have contributed to 
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the development of optic neuropathy in the past, is of certain importance 
at present. 
Because most heavy drinkers are also smokers, it is difficult to 
distinguish these two factors, and the term ‘tobacco-alcohol amblyopia’ is 
still commonly used. It now seems likely that there are two distinct 
disorders – tobacco optic neuropathy and nutritional optic neuropathy 
related to alcohol overconsumption. In the end of the 19th century, the 
role of nutritional deficit in provoking optic neuropathy was proposed, 
but it was in the middle of the 20th century when Carroll provided what 
appears to be the conclusive evidence (Carroll 1935, 1947, 1966); he 
showed that patients with TON partially or completely recovered their 
vision following vitamin B supplementation despite continuing their 
usual intake of alcohol and tobacco (Carroll 1966). 
Tobacco optic neuropathy is most often presented in elderly pipe-
smoking men; however, it was also reported in cigar smokers, users of 
chewing tobacco and users of snuff (Newman 1966). It is characterized 
by a bilateral relative centro-coecal field defect, more marked for a red or 
green target than white, and a characteristic disturbance of colour 
discrimination on the Farnsworth- Munsell 100 Hue Test . Vision can 
improve to normal or near normal over a period of 3–12 months if they 
stop smoking. 
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It was proposed that smoking, especially in genetically susceptible 
patients, might affect sulphur metabolism, leading to chronic cyanide 
intoxication and deficiency of vitamin B12. There are several reports 
confirming the coexistence of tobacco toxicity with deficiency of 
hydroxycobalamin (Heaton et al. 1958; Wokes 1958). On the other hand, 
most patients with TON have B12 levels within the normal range 
(Silvette et al. 1960). It was also proposed that genetic susceptibility 
overlaps with toxic environmental influences (Johns et al. 1993). As the 
clinical picture is not definitive, the diagnosis should be made after 
exclusion of the much more common nutritional optic neuropathy, other 
toxic optic neuropathies and congenital optic neuropathies, mainly 
LHON. Tobacco abstinence and oral and intramuscular B vitamins, 
particularly vitamin B1 and B12, were proposed as appropriate therapy 
(Younge 1996). 
. Environmental Factors and LHON Expression: Toxic and 
nutritional optic neuropathies are often classified as acquired 
mitochondrial optic neuropathies overlapping with congenital 
mitochondrial optic neuropathies, including LHON and dominant optic 
atrophy (DOA). 
NUTRITIONAL OPTIC NEUROPATHIES 
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Although a variety of nutritional deficiencies have been known for 
optic nerve dysfunction, many of these associations are anecdotal and the 
mechanism behind is uncertain. Multiple nutritional deficiencies are often 
present, and it is challenging to identify the specific vitamin responsible 
for the optic neuropathy g. With the exception of vitamin B12 deficiency, 
no other nutritional deficiency has been proven unequivocally to cause 
optic neuropathy. 
The prevalence of nutritional deficiency optic neuropathy is 
generally low in developed countries, but still its incidence may be 
increasing with the rise in gastric bypass procedures and secondary 
reduction in vitamin absorption. 
Some general rules are applicable to all optic neuropathies causally 
related to nutritional deficiency. (1) The patient must be nutritionally 
deficient for a long-enough period, usually several months, to deplete the 
nutrient stores. (2) Evidence of malnutrition (eg, weight loss, wasting) 
should be available, or a defined cause for the reduced vitamin level (eg, 
vitamin B12 deficiency in Crohn disease) should be determined. Other 
clinical findings which may support nutritional deficiency include 
peripheral neuropathy, keratitis, or cutaneous or mucous membrane 
changes. These need not be present always. 
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     The clinical findings are remarkably similar for nearly all forms of 
nutritional deficiency optic neuropathy. Rapid progression can occur in 
some cases. Visual loss in one eye and no findings in the other eye would 
argue strongly against nutritional deficiency optic neuropathy. The extent 
of visual acuity loss varies considerably. Since the non–papillomacular 
bundle fibers are spared visual acuity worse than hand motion is rare. 
Color perception is impaired early. Fundus examination may show 
temporal optic disc pallor, again indicating papillomacular bundle loss; 
however, the fundus may be completely normal early. All of the vitamins 
associated with nutritional deficiency optic neuropathy are involved in 
mitochondrial oxidative phosphorylation, and their deficiency would be 
expected to result in the energy depletion and the accumulation of free 
radicals. 
The diagnosis of nutritional deficiency optic neuropathy can be 
supported by laboratory evidence, including serum vitamin levels, serum 
protein concentration, or routine laboratory studies such as blood count 
(eg, showing a macrocytic anemia with vitamin B12 deficiency). 
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Vitamin B12–Deficiency Optic Neuropathy 
Vitamin B12 deficiency occurs in developed countries and most 
frequently in the setting of pernicious anemia. Other conditions that 
would result in vitamin B12 deficiency include damage to or surgical 
resection of the terminal ileum (in patients with Crohn disease) and 
previous bariatric surgery. Lack of vitamin B12 in the diet is the rarest 
cause, which is usually seen in strict vegans only. In addition to optic 
neuropathy, vitamin B12 deficiency can cause other conditions such as 
megaloblastic anemia,  subacute combined degeneration of the spinal 
cord and peripheral neuropathy. 28 
     Vision loss may precede anemia or any other neurologic symptoms. 
The diagnostic laboratory testing for vitamin B12 deficiency should 
include serum vitamin B12 levels; however, the diagnosis may not be 
straightforward always.Methylmalonic acid and homocysteine levels are 
both increased in vitamin B12 deficiency, and may suggest relative 
vitamin B12 deficiency even in the presence of low normal vitamin B12 
levels. Anyways, both methylmalonic acid and homocysteine levels can 
also be elevated in patients with renal insufficiency, and homocysteine 
level is influenced by a variety of factors, including tobacco and alcohol. 
Vitamin B12–deficiency optic neuropathy is one of the few nutritional 
deficiency optic neuropathies with good experimental evidence on causal 
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relationship. Primate models on this condition show that the optic 
neuropathy is caused by demyelination of nerve fibers. Studies suggest 
that the mechanism optic nerve injury may involve buildup of toxic levels 
of cyanide and also improper fatty acid synthesis leading to dysfunction 
of myelin. 
Prompt suspicion, recognition and treatment with parenteral 
hydroxycobalamin or high-dose oral vitamin B12might reverse the 
existing visual loss and prevent further visual deterioration. 
Folate Deficiency 
Folate deficient optic neuropathy is uncommon. Its early recognition and 
treatment are important to prevent the persistent visual defect. It is 
usually associated with starvation, malabsorption or excessive alcohol 
consumption. Dimness of vision is the outstanding symptom and it may 
be unilateral initially. It is a painless neuropathy. Alternative presenting 
symptoms are general loss of colour perception and dyschromatopsia. 
Other aspects of folate deficiency are axonal neuropathy, anaemia and 
encephalopathy. 
       It is possible that serum folate levels might be normal in the presence 
of true folate deficiency as red cell folate level is a more sensitive marker. 
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Hence, when folic acid deficiency is suspected, both serum and red cell 
folate levels should be analyzed. 
      The anterior visual pathway is prone to damage from toxins or 
nutritional deficiency. The exact mechanism by which nutritional deficits 
damage the optic nerve has not been elucidated yet but it is believed that 
the increased vascular supply of the optic nerve bundle increases its 
susceptibility to toxaemia. Folic acid is needed for the production of 
tetrahydrofolate, which is involved in the process of detoxification of 
formate. Formate accumulation inhibits cytochrome oxidase thereby 
blocking mitochondrial oxidative phosphorylation. 
  Folic acid deficient optic neuropathy has a good prognosis if 
treatment is initiated in the first few months after the onset of symptoms. 
It has been noted that visual acuity tends to recover before colour vision 
and when recovery is complete, recurrences are unusual 
Thiamine Deficiency 
 Thiamine (vitamin B1) is a cofactor for several mitochondrial 
enzymes, and in animal models thiamine deficiency results in impairment 
of cellular production of energy. Visual loss in the setting of thiamine 
deficiency is rare. Optic neuropathy has been reported in cases in 
association with Wernicke encephalopathy, traditionally in the context of 
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alcohol abuse and malnutrition. The incidence of Wernicke 
encephalopathy may be increasing because of the popularity of bariatric 
surgery, particularly gastric bypass, the procedure with the greater risk of 
subsequent malabsorption. The optic neuropathy associated with 
Wernicke encephalopathy is distinct from other forms of nutritional 
deficiency optic neuropathy to certain extent in that visual loss is often 
acute to subacute , and disc swelling (sometimes quite severe) is a 
prominent feature in most cases. The recovery of visual loss with 
appropriate thiamine supplementation is usually complete and often 
dramatic. 
The diagnosis of Wernicke encephalopathy–associated optic 
neuropathy is based on clinical features, neuroimaging findings, and 
response to thiamine treatment. Serum and plasma thiamine levels have 
poor sensitivity and specificity  (less than 10% of blood thiamine is 
contained in plasma); and, since delayed treatment may lead to 
irreversible neurologic injury, supplemental thiamine is often given 
empirically even before levels can be drawn. Whole blood thiamine 
testing is superior to serum or plasma levels, but results may take several 
days to obtain. An acute anterior optic neuropathy in the setting of 
malnutrition or previous gastric bypass procedure should raise suspicion 
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for Wernicke encephalopathy and prompt  diagnostic testing and 
supplementation with thiamine. 
 Reports suggest that optic neuropathy may be also associated with 
deficiencies in riboflavin, niacin, folic acid, and pyridoxine, but a causal 
relationship is uncertain. As these deficiencies are often found in severely 
malnourished patients,  identification of the specific vitamin deficiency 
leading to optic neuropathy is difficult. Copper deficiency has been 
reported to be associated with optic neuropathy.  
 A reasonable approach for patients with suspected nutritional 
deficiency optic neuropathy is to exclude other etiologies (with 
neuroimaging), and obtain vitamin B12 levels, complete blood cell count, 
and metabolic panel and to look for less common nutritional deficiency 
optic neuropathies (eg, thiamine, copper) if the initial screen is negative 
and clinical suspicion remains high. 
Work Up And Investigation In Case Of  Toxic And Nutritional Optic 
Neuropathy: 
The diagnosis of toxic or nutritional optic neuropathy is usually 
established by a detailed medical history and careful ocular 
examination.An extensive history may be the best way to uncover 
circumstances and situations that involve toxic neuropathy. Further 
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testing is led by the medical history and physical examination, and is 
performed to identify a specific toxin or nutritional deficiency as a cause 
of the optic neuropathy. Examples incude blood testing for vitamin B12 
levels. 
 Patients suspected of having a TON should have a complete 
hemogram, total and differential blood cell counts and urinalysis. The 
blood and urine also may be screened for specific toxins,especially if 
exposure to a particular one is not identified on history. On the otherhand, 
if a specific intoxicant is suspected one would try to identify it or its 
metabolites in the patient’s tissues or fluids. A heavy metal screening 
(lead,thallium) should be done based on suspicion. Serum B12 
(pernicious anemia) and red cell folate (marker of general nutritional 
status) should be obtained in any patient with bilateral central scotomas.A 
complete ocular examination for evaluating TON should include color 
vision and visual field testing. 
Visual field examination 
 Visual field evaluation, static (Humphrey) or kinetic(Goldman), is 
absolutely essential in the evaluation of any patient suspected of having 
toxic/ nutritional optic neuropathy. Central or centrocecalscotoma with 
preservation of peripheral field are characteristics of these optic 
neuropathies and are actually most prevalent in patients with theses 
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disorders. Rarely, patients may present with other defects. The field 
defects tend to be relatively symmetric. Soft margins are another 
characteristic of these defects, which are easier to define/ plot for colored 
targets, such as red , than for whitestimuli. 
Neuroimaging in toxic/ nutritional optic neuropathy. Although 
imaging studies yield normal results in toxic/ nutritional optic 
neuropathy, they almost always are indicated , unless one is a absolutely 
certain of the diagnosis. The most appropriate imaging is an magnetic 
resonance imaging (MRI) of the optic nerves and chiasm with or without 
gadolinium enhancement. If the medical history is atypical or does not 
clearly point to a cause, neuroimaging is required to rule out other causes 
and confirm the diagnosis. 
Management 
The first step in managing TON, as with any toxic process, is to 
remove the offending agent. This may cause some reversal of the process. 
Treatment of TON is dictated by the cause of the disorder. Medical 
therapy includes vitamin supplementation which is needed in many 
patients with toxic neuropathy especially those with tobacco alcohol 
amblyopia. 
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Patients with toxic/nutritional optic neuropathy should be observed 
initially 4-6 weeks and then, depending on their recovery, every 3-6 
months. The patient’s visual acuity , pupils, optic nerve head, color 
vision, and visual fields should be assessed at each visit.Vision gradually 
recovers to normal over several weeks, though it my take months for full 
restoration and there is always the risk of permanent residual vision 
deficit. Visual acuity usually recovers before color vision, the reverse of 
what happens at the onset of the disease process. 
     Morbidity of these disorders depends on the risk factors, the 
underlying etiology, and the duration of symptoms before the institution 
of treatment. A patient with advanced optic atrophy is less likely to 
recover visual function than a patient who does not have such 
pathological changes. The prognosis is variable and depends upon the 
nature of the agent, total exposure prior to removal, and degree of vision 
loss at the time of diagnosis.  
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AIM OF THE STUDY 
 The aim of this study is to evaluate the etiology and clinical profile 
of patients diagnosed with toxic and nutritional optic neuropathy 
attending Neuro Ophthalmology Clinic Aravind Eye Hospital, Madurai 
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MATERIALS AND METHODS 
STUDY POPULATION: 
 All clinically proven cases of toxic and nutritional optic neuropathy 
attending  Neuro ophthalmology Clinic,  Aravind Eye Hospital , Madurai  
who are willing to participate in my study. 
STUDY DESIGN :Prospective, observational study 
STUDY PERIOD : December 2015 to February 2017 
INCLUSION CRITERIA: 
All clinically proven cases of nutritional and toxic optic neuropathy  with  
visual dysfunction (visual acuity, colour vision and/or visual field loss) 
attributable to the optic nerve pathology.  
EXCLUSION CRITERIA: 
Patients with history of trauma   
Patients with co existing ocular pathology such as corneal 
dystrophy, corneal opacity, diabetic retinopathy, glaucoma,etc 
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METHODOLOGY 
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History on various toxins and 
nutritional depletions along with 
diet history to assess nutritional 
status
Detailed Ocular examination which 
includes visual acuity, pupil, colour vision, 
central fields, fundus to assess the ocular 
pathology and rule out concomitant illness 
Toxic optic  neuropathy 
with no nutritional  
deficiency
Toxic optic neuropathy 
with nutritional 
deficiency 
Nutritional optic 
neuropathy 
Eliminate toxin Eliminate toxin with  
vitamin 
supplementation
Vitamin 
supplementation
Follow Up  at 3 Months with Visual Acuity, 
Colour Vision, Central Fields, Fundus
 
STATISTICAL METHODS : 
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Continuous and categorical variables were expressed as mean(SD) 
and frequency (percentage) respectively. 
Wilcoxon Sign Rank test was used to assess the difference between 
continuous variables. 
McNemar’s test or Fischer’sexact testwas used to assess the association 
between categorical variables. 
 
 
 
 
 
 
 
 
 
 
RESULTS 
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SEX DISTRIBUTION: 
Chart 1 
 
Table 1: 
Gender n Percentage 
Male 31 68.9 
Female 14 31.1 
Total 45 100 
Total number of patients: 45 
No. of males     :31No. of females : 14 
 
AGE DISTRIBUTION 
MALES 
69% 
FEMALES 
31% 
SEX DISTRIBUTION 
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<20 21-30 31-40 41-50 51-60 61-70 >70
4 
6 
13 
10 
6 
5 
1 
AGE DISTRIBUTION 
Chart 2 
Table 2: 
Age N Mean SD 
Min – 
Max 
Age in 
years 
45 41.51 14.8 15 -72 
 
No. of patients <40 yrs : 23 
No.of patients > 40 yrs: 22. 
The most number of patients in our study were in the age group of 31 – 
40 years.  
The mean age in our study population was 41 years. 
There was only one patient in our study group greater than 70 years. 
DISEASE DISTRIBUTION 
Chart 3: 
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No.of cases diagnosed with toxic optic neuropathy     :39 
No.of cases diagnosed with nutritional optic neuropathy :4 
No.of cases diagnosed with toxic and nutritional optic neuropathy :2 
 
 
 
 
 
Chart 4: 
TOXIC OPTIC
NEUROPATHY
TOXIC &
NUTRITIONAL
OPTIC
NEUROPATHY
NUTRITIONAL
OPTIC
NEUROPATHY
86.58% 
4.44% 8.90% 
DISEASE DISTRIBUTION 
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No.  of cases diagnosed with  toxic optic neuropathy due to alcohol : 2 
No.ofcases diagnosed with toxic optic neuropathy due to tobacco : 13 
No. of cases diagnosed with toxic optic neuropathy due to alcohol and 
tobacco :16 
No. of cases diagnosed with toxic optic neuropathy due to 
antituberculousdrug : 8 
Alcohol and tobacco on a combination appears to be the major addictive 
in causing disease complaints.  
ATT has been causing optic neuropathy since time immemorial and 
hence periodic consultation with regards to visual effects has to be borne 
in mind and effective dose reduction /drug cessation has to be in place. 
 
TOXIC AND NUTRITIONAL OPTIC NEUROPATHY 
ALCOHOL 
5% 
TOBACCO 
33% 
ALCOHOL & 
TOBACCO 
41% 
ATT 
21% 
TOXIC OPTIC NEUROPATHY 
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Chart 5: 
 
 
No. of cases diagnosed with toxic and  
vitamin B12 deficiency optic neuropathy          : 1 
No. of cases diagnosed with toxic and  
folate deficiency optic neuropathy                      : 1              
Hence two patients with toxic optic neuropathy had a concomitant 
nutritional deficiency in the form of vitamin B12 or folate. 
The assessment in these patients holds high regard as in addition to 
cessation of the toxic component , consumption of specific nutritional 
supplements has to be also addressed. 
50% 50% 
TOXIC OPTIC NEUROPATHY 
ASSOCIATED WITH NUTRITIONAL 
DEFICIENCY 
Vitamin B12
deficient
Folate deficient
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NUTRITIONAL OPTIC NEUROPATHY 
Chart 6: 
 
No. of  cases diagnosed with nutritional optic neuropathy 
due to vitamin B12 deficiency                                                  : 3 
No. of cases diagnosed with nutritional optic neuropathy 
due to folate deficiency                                                             : 1 
Among the nutritional deficient optic neuropathies, vitamin B12 seems to 
be the most common. 
Vitamin B12 
deficiency 
75% 
Folate 
deficiency  
25% 
NUTRITIONAL OPTIC NEUROPATHY 
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COLOUR VISION 
FOLLOW UP  :Table 3 
 
Table 4: 
Colour 
Vision 
Base Line 
n(%) 
3rd Month Follow-up 
n(%) 
P-Value* 
Defective 35 (77.7) 32 (71.1) 
0.031 
Normal 10 (22.2) 13 (28.9) 
Total 45 45  
*McNemar’s test 
The P-value (<0.05) shows that there is significant difference between the 
base line and follow-up colour vision. 
Colour Vision 3rd Month follow-up n(%) 
Defective With Improvement 15 (33.3) 
Defective With  No Improvement 17 (37.8) 
Normal 13 (28.9) 
Total 45 
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COLOUR VISION : 
Chart 7: 
 
 
Chart 8: 
 
 
NORMAL 
22% 
DEFECTIVE 
78% 
BASELINE 
COLOUR VISION 
0% 
DEFECTIVE 
71% 
NORMAL 
29% 
3RD MONTH FOLLOW UP 
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CENTRAL FIELDS 
 
Table 5: 
 
Central 
field 
Base line 
n(%) 
3rd MonthFollow-
upn(%) 
P-Value* 
Defective 12 (26.7) 9 (20.0) 
0.031 
Normal 33 (73.3) 36 (80.0) 
Total 45 45  
*McNemar’s test 
 
The P-value (<0.05) shows that there is significant difference in the 
central field between the base line and 3rd month follow-up. 
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Table 6: 
Central Field 
Base Line 
n(%) 
3rdMonth Follow-up 
n(%) 
Central Scotoma 4 (33.3) 4 (44.4) 
CentrocecalScotoma 7 (58.3) 4 (44.4) 
Peripheral Field 
Constriction 
1 (8.3) 1 (11.1) 
Total 12 9 
Among the defective central fields, centrocaecalscotoma accounted 
for the maximum number of patients affected followed by central 
scotoma and peripheral field constriction. 
The improvement was also in patients suffering from 
centrocaecalscotoma accounting for 3 amongst the seven  affected. 
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Central Field Defects 
 
Chart 9: 
 
 
 
 
 
 
CENTROCECAL 
SCOTOMA 
59% 
CENTRAL 
SCOTOMA 
33% 
PERIPHERAL FIELD 
CONSTRICTION 
8% 
BASELINE 
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Chart 10: 
DEFECTIVE(27
%)
NORMAL(73%)    
BASELINE(n)
 
Chart 11: 
DEFECTIVE
20%
NORMAL
80%
3RD MONTH FOLLOW UP(n)
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FOLLOW UP – FUNDUS 
Table 7: 
Fundus 
Base line 
n(%) 
3rd Month Follow-
upn(%) 
P-Value* 
Defective 43 (95.6) 37 (82.2) 
0.001 
Normal 2 (4.4) 8 (17.8) 
Total 45 45  
*McNemar’s test 
The P-value (<0.05) shows that there is significant difference in the 
fundus report between the base line and follow-up. 
The findings noted were hyperaemia , pale disc , temporal pallor or 
normal. 
Of all the above findings, temporal pallor was noted in most of the 
study population. 
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Table 8 
Fundus 
Base Line 
n(%) 
3rd Month Follow-
up n(%) 
HYPEREMIC 2 (4.4) - 
PALE DISC 1 (2.2) 1 (2.2) 
TEMPORAL PALLOR 40 (88.9) 36 (80.0) 
NORMAL 2 (4.4) 8 (17.8) 
Total 45 45 
 
 Hyperemia and temporal pallor have been seen to resolve over a 3 
month follow up on cessation of the toxin or improvement 
nutritionally. 
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Fig 2:FUNDUS OF BOTH EYES SHOWING TEMPORAL 
PALLOR 
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Chart 12: 
 
 
Chart 13: 
 
HYPEREMIC 
9% 
TEMPORAL 
PALLOR 
78% 
PALE DISC 
4% 
NORMAL 
9% 
BASELINE 
HYPEREMIC 
0% 
TEMPORAL 
PALLOR 
80% 
PALE DISC 
2% 
NORMAL 
18% 
3RD MONTH FOLLOW UP 
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BEST CORRECTED VISUAL ACUITY (BCVA)  – FOLLOW UP 
Table 9 
BCVA Eyes(n) Median Min – Max P-value@ 
Base Line 90 6/18 (0.48) 6/6 – 2/60 
0.001 3rd Month 
Follow-up 
90 6/12 (0.3) 6/6 – 4/60 
@
 Wilcoxon Sign Rank Test 
The P-Value (<0.05) shows that there is a statistical significant 
difference between the base line and 3rd month follow-up of BCVA. 
The median BCVA was 6/ 18 on the baseline that had an 
improvement to 6/12 on follow up. 
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Chart 14: 
 
 
 
 
 
 
 
 
 
 
MEAN BASELINE BCVA MEAN FOLLOW UP BCVA
FREQ 0.53 0.39
0
0.1
0.2
0.3
0.4
0.5
0.6
LO
G
M
A
R
 V
A
LU
E
 
BCVA 
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DISCUSSION 
 Toxic and nutritional optic neuropathy has no age and sex 
predilection as proven by earlier studies. In our study, majority of the 
cases were males and in the fourth decade , accounting for 28.88 %, while 
22.22 % belonged to the second and third decade put together and another 
22.2 % belonged to the fifth decade. 
 This is to highlight the fact that nearly 3/4 th of the study group 
belonged to the working population and hence early disease process 
identification will have a greater impact on their lifestyle. In our study, 
males out numbered females ( 69% vs 31%). 
Toxic optic neuropathy accounted for the majority of the cases in 
our study (86.58%) while nutritional optic neuropathy accounted for 
around 9 %. The combination of both were around 4.44%. So, the 
nutritional component in patients with toxic optic neuropathy accounted 
for around 4%. This subset was distributed equally among the B12 and 
folate deficient groups.  
Henceforth these patients with toxic optic neuropathy should be 
identified and supplemented with adequate nutrients for clinical 
improvement. This aspect is consistent with earlier studies by 
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PradeepSharma et al that emphasizes the concept of concomitant 
nutritional deficiency in toxic optic neuropathy. 
 Coming to individual components in toxic neuropathy alcohol and 
tobacco consumption together accounted for the maximum number 
(40.96%), with tobacco alone being 33.28%, anti tubercular drug toxicity 
around 21% and alcohol in 5% of the study population.  
According to Michal et al,ethanol-induced optic neuropathy is not 
frequently reported. Clinical picture of chronic alcoholic neuropathy may 
include: peripheral neuropathy (e.g. limb weakness, numbness, 
diminished tendon reflexes) and optic neuropathy. Visual loss is painless 
and bilateral, it can be of various severity.  
 Loss of central vision may be chronic or subacute, it is usually 
accompanied by decreased visual acuity and dyschromatopsia. Some 
individuals lose vision rapidly and a usual late consequence is optic 
atrophy which develops after one to two months and leads to total 
blindness. Visual field test characteristically shows central and 
centrocecalscotomas. In severe cases, pupillary dilatation can be found, it 
usually signifies a poor prognosis, as it occurs in almost total or total 
blindness. The eye fundus may appear normal, although there may be 
abnormalities, especially atrophy of the optic disc. In acute intoxication 
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the optic discs may appear swollen and hyperemic, the edema may extend 
to the surrounding retina.31,32 
Shimozono et al. described a case of nutritional optic atrophy with 
permanent vision loss, central scotoma, and an acquired red-green color 
vision defect. They concluded that alcohol-induced nutritional optic 
neuropathy should not be viewed as an isolated ocular entity, but rather as 
a potentially treatable neurologic problem. 
Loss of central vision may be chronic or subacute, it is usually 
accompanied by decreased visual acuity and dyschromatopsia. Some 
individuals lose vision rapidly and a usual late consequence is optic 
atrophy which develops after one to two months and leads to total 
blindness.  
Visual field test characteristically shows central and 
centrocecalscotomas. In severe cases, pupillary dilatation can be found, it 
usually signifies a poor prognosis, as it occurs in almost total or total 
blindness. The eye fundus may appear normal, although there may be 
abnormalities, especially atrophy of the optic disc. In acute intoxication 
the optic discs may appear swollen and hyperemic, the edema may extend 
to the surrounding retina.  
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The visual symptoms usually start 2–8 months after the drug is 
started. Pupillary abnormalities can be subtle, and visual evoked potential 
may be needed to conﬁrm the diagnosis. The diagnosis is often made late 
when optic nerve pallor has already set in and vision is severely affected. 
The drug should be stopped as soon as the diagnosis is made, although in 
advanced cases vision continues to deteriorate even following drug 
cessation. 
Our study is also consistent with similar results as most of the 
patients affected had a centrocaecalscotoma. In addition, in contrast to the 
above study results , the fundus had temporal pallor in most of the cases. 
Hyperemia was found in less number of cases. 
According to  Su-Ann Lim, patients with impaired renal function 
from renal tuberculosis may be more prone to ethambutol-associated 
optic neuropathy; perhaps because ethambutol depends on the kidneys for 
excretion.33,34 It is also important for the clinician to be aware that there 
are reports of rapid onset, severe, bilateral visual loss despite treatment 
with therapeutic doses of ethambutol.35,36 Patients taking ethambutol 
should be instructed to discontinue the drug immediately at the onset of 
any visual symptoms and seek medical consult. 
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According to Orssaud et al, early withdrawal from all sources of 
intoxication is essential for visual recovery but this goal is often difficult 
to obtain given the poor treatment compliance of addicted patients. 
The prognosis of these optic neuropathies is variable and depends 
on the available treatments. In general, a favourable recovery with almost 
complete return of vision is obtained when the treatment is established as 
early as possible; although sequels can persist.37 
Patients with normal B12 absorption and normal levels of B12 in 
the serum may also develop amblyopia if they smoke heavily enough. 
These facts would fit the suggestion that tobacco amblyopia is the result 
of a failure to detoxify cyanide derived from tobacco smoke (Wokes, 
1958; Smith, I961) and that B12, particularly in its hydroxy form, is 
necessary for this detoxification (Smith, I968)38. 
In our study, the toxic component causing optic symptomatology , 
though identified early, concomitant corroboration with renal functions 
has not been established.The results have been satisfactory on drug 
withdrawal. 
Isolated nutritional optic neuropathy accounting for 9% had B12 as 
the deficient component in majority of the cases while the remaining 
were deficient in folate. Other studies demonstrate the fact that 
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measurement / assay of individual component levels have not been done 
and have pumped in vitamins in a broad range. 
 The best corrected visual acuity improved from a baseline 6/18 to 
6/12 in our study population with a statistically significant p value of less 
than 0.001. 33.3% of the population showed improvement in colour 
vision with a statistically significant p value.  
As there are no earlier studies, regarding the same, comparison and 
standardization is not feasible. 
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CONCLUSION 
According to our study, 
 Males are the common study population affected, with most of 
them belonging to fourth decade, thus mandating effective early 
diagnosis and treatment to improve outcomes. 
 Toxic optic neuropathy over ruled nutritional optic neuropathy and 
hence early effective drug withdrawal showed prompt relief. 
 A section of the study group had a nutritional counterpart 
deficiency when suffering from toxic optic neuropathy. These 
patients have to be identified and adequate specific nutritional 
supplements have to be given  in addition to cessation of the 
offending agent to address the pathology more specifically. 
 Vitamin B12 deficiency optic neuropathy was reported more 
precedingfolate deficiency as per our study. Hence evaluation and 
monitoring of their serum levels have to be borne in mind when 
treating these patients. 
 Visual acuity ,colour vision , central fields and  fundus changes 
have to be monitored periodically once in three months to evaluate 
effective treatment strategies. 
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 Centrocaecalscotoma was found in most of the affected patients 
with temporal pallor taking a overhaul. Hence these changes have 
to be keenly looked for in patient evaluation. 
 Further , nutritional compliance with these patients is a major 
challenge which has to be overcome with emphasis on its 
importance on follow up. 
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LIMITATIONS 
 Our study in on a small sample size and hence cannot be 
extrapolated to the entire population. Further studies on larger 
population groups is essential. 
 Deficiency in the form of trace elements could not be evaluated 
and has to be included as a part of future research. 
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ANNEXURE 
 
 
                                                             
PROFORMA 
 
 
CASE NO                                                                                                                            DATE: 
PARTICIPANT NAME:                                                                  AGE :                          GENDER:                                                                               
M.R. NO.:                                                                                                                          OCCUPATION 
ADDRESS 
 
CONTACT NO. 
 
COMPLAINTS 
H/O TRAUMA                       - YES/ NO 
PAST HISTORY 
DIABETES                               -  YES/ NO 
 ( IF YES, ON WHAT DRUG)     
HYPERTENSION                    -  YES/ No  
TUBERCULOSIS                    - YES/ NO    (IF YES , DETAILS OF TREATMENT) 
H/O ANY ABDOMINAL SURGERIES IN PAST – YES/ NO 
DEFECTIVE  VISION DURATION – 
(in months/years) 
 
UNILATERAL / BILATERAL 
 
SUDDEN/INSIDIOUS 
 
PROGRESSIVE/STATIONARY 
 
PAINLESS/PAINFUL 
 
FIELD DEFECTS YES/ NO 
IF YES , WHEN ?   PRE OPERATIVE DIAGNOSIS ?  PROCEDURE ? 
ANY OTHER SIGNIFICANT ILLNESS  – 
DRUG HISTORY: 
DISEASE PROCESS   YES    NO TREATMENT   YES    NO 
HEART AILMENTS (ARRYTHMIAS)   ON ANTIARRYTHMICS  
(AMIODARONE, DIGITALIS) 
  
KNOWN CASE OF TUBERCULOSIS   ON ANTITUBERCULOUS TREATMENT 
(ETHAMBUTOL, ISONIAZID, OTHERS) 
  
RECENT ONSET OF SYSTEMIC ILLNESS   ON ANTIBIOTICS  
(CHLORAMPHENICOL, LINEZOLID, 
SULPHONAMIDES) 
  
MALIGNANCY   ON TREATMENT  
(VINCRISTINE, METHOTREXATE) 
  
MALARIAL ILLNESS   ON ANTIMALARIALS  
( QUININE, 
CHLOROQUINE) 
  
CHRONIC HEAVY METAL EXPOSURE 
(LEAD, MERCURY) 
     
ANY OTHERS      
IF YES , MENTION DRUG CONSUMED AND DURATION 
DIET HISTORY : VEG / NON VEG 
H/O ALCOHOL CONSUMPTION: YES/ NO    IF YES,    DURATION -     
1- YES             2 - NO 
H/O TOBACCO INGESTION :  YES/NO   DURATION   -    MODE   -     
         1 – YES             2 - NO 
 
GENERAL EXAMINATION 
BUILT      :   
BODY MASS INDEX : 
PALLOR  :  YES/ NO 
PULSE RATE : 
BLOOD PRESSURE : 
 
ORAL EXAMINATION : 
          GLOSSITIS :   YES/ NO;   TOBACCO STAINING :  YES/ NO; ANGULAR STOMATITIS : YES / NO 
DERMATOLOGICAL EXAMINATION: 
           DERMATITIS :  YES/ NO 
NEUROLOGICAL EXAMINATION: 
Pain sensation :   PRESERVED / LOST 
Touch sensation :                           PRESERVED / LOST 
Pressure sensation :                          PRESERVED / LOST 
Vibration sense :   PRESERVED / LOST 
Proprioception :   PRESERVED / LOST 
OCULAR EXAMINATION 
 
 RIGHT EYE LEFT EYE 
UCVA 
 
  
BCVA 
 
  
INTRAOCULAR PRESSURE 
 
  
ANTERIOR SEGMENT 
 
  
PUPIL: 
1.NORMAL 
2. SLUGGISH 
3.RAPD 
  
COLOUR VISION 
1.NORMAL 
2.DEFECTIVE 
  
CENTRAL FIELDS  
1.NORMAL                                                 
2.CENTRAL SCOTOMA 
 3.CENTROCECAL SCOTOMA 
4. PERIPHERAL FIELD       
  
CONSTRICTION 
FUNDUS: 
 1.NORMAL 
 2.TEMORAL PALLOR 
 3.PALE DISC 
 4.HYPEREMIA 
 5.DISC EDEMA 
  
 
INVESTIGATIONS: 
VITAMIN B12  
1- NORMAL  ; 2 - DECREASED 
SERUM FOLIC ACID  
1- NORMAL ;2 - DECREASED 
CT SCAN/MRI SCAN 
1- Non compressive optic neuropathy 
 
TREATMENT 
REMOVAL OF THE DRUG/TOXIN 
VITAMIN SUPPLEMENTATION (PARENTERAL AND ORAL) 
 
 
FOLLOW UP AT 3 MONTHS 
 RIGHT EYE LEFT EYE 
UCVA 
 
  
BCVA 
 
  
INTRAOCULAR PRESSURE 
 
  
ANTERIOR SEGMENT 
 
  
PUPIL: 
1.NORMAL 
2. SLUGGISH 
3.RAPD 
  
COLOUR VISION 
1.NORMAL 
2.DEFECTIVE WITHOUT 
IMPROVEMENT 
3. DEFECTIVE WITH 
IMPROVEMENT 
  
CENTRAL FIELDS  
1.NORMAL                                                 
2.CENTRAL SCOTOMA 
 3.CENTROCECAL SCOTOMA 
4. PERIPHERAL FIELD       
CONSTRICTION 
  
FUNDUS: 
 1.NORMAL 
 2.TEMORAL PALLOR 
 3.PALE DISC 
 4.HYPEREMIA 
 5.DISC EDEMA 
  
 
 
 
 
Informed Consent form to participate in a clinical study 
Study Title: A STUDY ON CLINICAL PROFILE OF TOXIC AND NUTRITIONAL 
OPTIC NEUROPATHY 
 
Protocol Number: 
  
Subject’s Name: _______________Subject’s Initials: _______________  
  
Subject ID No: _________________ Date of Birth / Age: _________________  
  
    Please put initial 
in the box 
(Subject) 
(i) I confirm that I have understood the information about the study, 
procedures and treatments for the above study and have had the 
opportunity to ask questions and I received satisfactory answers to 
all of my questions.  I have been given a copy of the informed 
consent form to take home 
  
[         ] 
(ii) I understand that my participation in the study is voluntary and that I 
am free to withdraw at any time, without giving any reason, without 
my medical care or legal rights being affected. However, this is may  
not be possible for certain surgical procedures  
 
[         ] 
(iii) I understand that the Investigator of the study to access my health 
records for the research purpose. However, I understand that my 
identity will not be revealed in any information released to third 
parties or published. 
[         ] 
(iv) I agree not to restrict the use of any data or results that arise from 
this study provided such a use is only for scientific purpose(s) 
 
[        ] 
  
(v) I agree to take part in the above study. 
  
          [         ] 
    
  
Signature (or Thumb impression) of the Subject: _____________________________  
  
 Date: _____/_____/______ 
  
Subject’s Name: ______________________________________________________ 
  
 
Signature (or Thumb impression) of Legally Acceptable Representative (LAR): 
 
 
___________________________________________              Date: ____________  
 
 
 
Signature of the Investigator: ___________________________Date: _____/_____/______ 
  
Investigator’s Name: __________________________________________________ 
  
 
 
 
Signature of the Witness ______________________               Date:_____/_____/_______  
  
Name of the Witness: _______________________________________________________ 
 

  
 
PLAGIARISM  REPORT 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 

SEX 1 MALE 
 2 FEMALE 
COMPLAINTS 1 DEFECTIVE VISION 
EYE 1 RIGHT EYE 
 2 LEFT EYE 
 3 BOTH EYES 
SYSTEMIC ILLNESS 0 NIL 
 1 DIABETES 
 2 HYPERTENSION 
 3 DM&HT 
ALCOHOL 1 YES 
 2 NO 
TOBACCO 1 YES 
 2 NO 
ANTITUBERCULOUS DRUG 
INTAKE 
0 ATT COMPLETED 
 1 ON ATT 
 2 NO 
PUPIL 1 NORMAL 
 2 SLUGGISH 
 3 RAPD 
COLOUR VISION 1 NORMAL 
 2 DEFECTIVE 
 3 NOT ASSESSABLE 
CENTRAL FIELDS 1 NORMAL 
 2 CENTRAL SCOTOMA 
 3 CENTROCECAL SCOTOMA 
 4 PERIPHERAL FIELD 
CONSTRICTION 
FUNDUS 1 NORMAL 
 2 TEMPORAL PALLOR 
 3 PALE DISC 
 4 HYPEREMIA 
 5 DISC EDEMA 
CT/MRI BRAIN  1 NON COMPRESSIVE OPTIC 
NEUROPATHY 
VITAMIN B12 1 NORMAL 
 2 DECREASED 
S. FOLIC ACID 1 NORMAL 
 2 DECREASED 
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